The Blunt Truth

DECEMBER 22, 2023

UNITED STATES ATTORNEYS Attorney General Merrick Garland and DEA Administrator Anne Milgram received a letter this week from several former United States Attorneys. The letter raises concerns about the potential for abuse, a lack of medical treatment potential, and trafficking by criminal gangs. Look for more on this in 2024 also.

DEA 52

DEA Retail Programs Hemp 52

The Blunt Truth

OCTOBER 24, 2019

The 2019 edition of the Hemp and CBD Industry Factbook released figures that show retail sales of CBD topping $1 billion this year, and predicted that number could hit $10 billion by 2024. Tourette syndrome and intractable neuropathic pain are now eligible for treatment with medical cannabis.

Hemp 58

Hemp DEA CBD Topical 58

Medicinal Genomics

JULY 13, 2023

one of just seven federally DEA- licensed cannabinoid research labs, had some encouraging news about how cannabinoids and cannaflavins can lengthen life spans while improving health spans. Watch Dr. Russo’s Presentation Hunter Land, Ph.D, the VP of Research & Development at Biopharmaceutical Research Company, Inc.,

Research and Development 52

Research and Development Cannabinoids Medicine DEA 52

Cannabis Law Report

MAY 31, 2022

Food and Drug Administration (FDA) approved esketamine (a component of Ketamine and sold under the brand name Spravato) for treatment-resistant depression. The Drug Enforcement Agency (DEA) currently has guidance published for those interested in petitioning for a religious exemption to the CSA. On March 5, 2019, the U.S.

Clinical Trials 52

Clinical Trials Legalization Therapy Decriminalization 52

The Cannigma

MAY 15, 2023

While costs to access ketamine therapy can be high in some locations, and like any drug ketamine is not a cure-all, some patients and their doctors have been reporting life-changing results when no other treatment provided relief. Patients may want to seek assistance from a certified professional prior to embarking on treatment.

Therapy 78

Therapy Access Blood Pressure Treatment 78

Cannabis Law Report

SEPTEMBER 12, 2022

Government Agencies seek funding to research cannabinoids as treatments for various conditions: [link]. Virginia 2024 adult use program may be postponed: [link]. DEA grants research license for psychedelics and major depression first human trial: [link]. Cannabinoids. Delta 8 now legal in Kentucky: [link].

DEA 98

DEA Hemp Dispensary Therapy 98

The Blunt Truth

OCTOBER 3, 2019

In Connecticut , meanwhile, the state may add chronic pain to the list of conditions eligible for treatment with medical marijuana. In the world of hemp, Senator Mitch McConnell has directed the DEA to figure out how to distinguish hemp from marijuana.

Chronic Pain 77

Chronic Pain Hemp DEA Programs 77